|
SPG21 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.39980000035678E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.02550000000446E-07 |
| Normal-vs-Stage2 |
1.942270E-03 |
| Normal-vs-Stage3 |
1.55499999998643E-06 |
| Normal-vs-Stage4 |
1.58410999999692E-05 |
| Stage1-vs-Stage2 |
6.745400E-01 |
| Stage1-vs-Stage3 |
6.838000E-01 |
| Stage1-vs-Stage4 |
6.275400E-01 |
| Stage2-vs-Stage3 |
5.363600E-01 |
| Stage2-vs-Stage4 |
5.103400E-01 |
| Stage3-vs-Stage4 |
8.754000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.31370000433506E-08 |
| Normal-vs-AfricanAmerican |
1.748170E-02 |
| Normal-vs-Asian |
1.062750E-03 |
| Caucasian-vs-AfricanAmerican |
1.896420E-01 |
| Caucasian-vs-Asian |
2.321200E-01 |
| AfricanAmerican-vs-Asian |
7.209600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.02250000028259E-07 |
| Normal-vs-Female |
6.27709999978521E-07 |
| Male-vs-Female |
2.214400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00279999970532E-07 |
| Normal-vs-Age(41-60Yrs) |
1.90080999999953E-05 |
| Normal-vs-Age(61-80Yrs) |
1.55389999999533E-05 |
| Normal-vs-Age(81-100Yrs) |
2.943000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.715000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.673200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.647000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.725400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.188400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.777400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.700000E-01 |
| Classical-VS-Follicular |
5.689200E-01 |
| Classical-VS-Other |
6.871800E-01 |
| Classical-VS-Normal |
8.59569999622778E-08 |
| Tall-VS-Follicular |
3.219600E-01 |
| Tall-VS-Other |
9.778000E-01 |
| Tall-VS-Normal |
7.95810000000508E-05 |
| Follicular-VS-Other |
6.434200E-01 |
| Follicular-VS-Normal |
6.591900E-04 |
| Other-VS-Normal |
1.958180E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.83589999997103E-06 |
| Normal-vs-N1 |
6.36909969209398E-10 |
| N0-vs-N1 |
1.001940E-02 |
|
|
